UPDATED: Teva's struggling sterile plant hit with FDA warning letter | Fierce Pharma
Amicus Therapeutics: Finally The FDA Inspection Is Done (NASDAQ:FOLD) | Seeking Alpha
Teva Pharma Suspends Irvine Production After FDA Probe - Orange County Business Journal
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
Filling errors, counterfeit packs gain FDA's attention | Packaging World
Celltrion FDA warning causes headache for Teva's biologics ambition
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Complete Response Letter Received for AVT02 Biologics License Application
FDA to share full inspection reports with EU; Difficult week for Teva, J&J, Mylan | Radio Compass Blog
Teva Issues Voluntary Nationwide Recall of One Lot of IDArubicin Hydrochloride Injection USP 5 mg/5 mL Due to the Presence of Particulate Matter | FDA
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Teva Pharmaceutical Works Private Limited Company 10/13/16
Site Inspections | Teva api
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Teva plant tagged with warning letter for issues making schizophrenia drug | Fierce Pharma
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Teva recalls US-made drugs following contamination fears - The Boston Globe
FDA Warns Teva API Plant in China | RAPS
Teva Recalls U.S.-Made Drugs Following Contamination Fears | 2021-10-04 | SupplyChainBrain
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Teva Recalls One Lot Of IDArubicin Hydrochloride Injection
Teva stock drops on guidance, manufacturing problems - MarketWatch
Troubled Teva plant in Hungary faces an FDA crackdown - STAT
Cheap Prescription Drugs in U.S. Can Have Hidden Cost - Bloomberg
FDA Warning Letter To Teva Highlights Need For Accurate Root Cause Investigations :: Pink Sheet
Teva's struggling sterile plant hit with FDA warning letter - Skyland Analytics
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
